Sotyktu (Deucravacitinib)

Save 66% on Brand Sotyku from Europe.

Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.

According to the European Medicines Agency, brand name Sotyktu originating from Europe is manufactured at the following site(s):Swords Laboratories Unlimited Company T/A Bristol-Myers Squibb Pharmaceutical Operations External Manufacturing Plaza 254 Blanchardstown Corporate Park 2 Dublin 15, D15 T867 Ireland

Information about Sotyktu (Deucravacitinib)

Sotyktu is a medication containing deucravacitinib, an oral selective inhibitor of Janus kinase (JAK). It is used to treat certain autoimmune and inflammatory conditions by targeting specific enzymes involved in the immune system’s inflammatory processes. By inhibiting these enzymes, Sotyktu helps reduce the activity of the immune system that leads to inflammation and tissue damage. Deucravacitinib is used primarily in the treatment of moderate to severe plaque psoriasis, a condition where the immune system causes the skin cells to multiply rapidly, leading to thick, scaly patches.

Product Highlights

• Sotyktu is used in adults with moderate to severe plaque psoriasis who are suitable for systemic therapy. Plaque psoriasis is characterized by red, swollen skin covered with silvery scales. 
• While primarily used for psoriasis, Sotyktu may also be investigated for other autoimmune conditions as part of ongoing research.

Key Ingredient

• Deucravacitinib

Key Benefits

• Sotyktu has shown significant effectiveness in reducing the symptoms of moderate to severe plaque psoriasis, improving skin appearance and quality of life.
• Unlike topical therapies, Sotyktu offers the convenience of an oral medication for patients who may find topical treatments difficult to use or insufficient.
• Sotyktu has a relatively quick onset of action, with many patients experiencing noticeable improvements in their symptoms within a few weeks of starting treatment.
• By selectively inhibiting JAK1, Sotyktu is designed to reduce the side effects associated with broader immune suppression that can occur with less targeted treatments.

Direction of Use

• The standard dosage of Sotyktu is a 6 mg tablet taken orally once every day. The exact dosage may vary depending on the individual’s response to the medication, and healthcare providers will adjust the dose accordingly.
• Sotyktu is taken with or without food. It is essential to take the medication exactly as directed by a healthcare provider, without missing any doses. 
• For best results, Sotyktu should be taken continuously as prescribed. However, patients should have regular follow-up visits to monitor for side effects and to assess treatment efficacy.

Safety Concerns

• Sotyktu may raise the risk of severe infections due to its potential to suppress the immune system. Patients should be monitored for signs of infections, including tuberculosis, pneumonia, and other serious infections.
• Deucravacitinib can affect liver function, so liver enzyme levels should be regularly monitored during treatment.
• JAK inhibitors like Sotyktu can increase the risk of blood clots. Patients with a history of blood clotting disorders or those at risk should be monitored closely.
• Long-term use of JAK inhibitors has been associated with an increased risk of certain cancers, including lymphomas and other malignancies.
• Regular blood tests to monitor liver function, blood cell counts, and lipid levels are recommended while on treatment with Sotyktu.
• Common side effects may include headache, diarrhea, upper respiratory tract infections, nausea, and fatigue. Serious side effects include infections, liver damage, and blood-related disorders.

Avoid Sotyktu (Deucravacitinib) If

• If a patient has an active infection, particularly serious infections such as tuberculosis, fungal infections, or viral infections, Sotyktu should be avoided until the infection is treated.
• Sotyktu is not recommended for use during pregnancy or breastfeeding due to potential risks to the fetus or infant. Women who are capable of becoming pregnant should use reliable contraception during treatment. 
• Patients with severe liver impairment should avoid Sotyktu or use it under close medical supervision, as it can affect liver function.
• Individuals with a history of blood clots, stroke, or clotting disorders should avoid Sotyktu or use it with caution, as it may increase the risk of blood clots.
• Patients with a history of cancers, particularly blood-related cancers like lymphoma, should discuss the potential risks of Sotyktu with their healthcare provider.
• Sotyktu should not be used in patients with a known allergy to deucravacitinib or any of the inactive ingredients in the medication.